FisherB., RedmondC., DimitrovN.V.: A randomized clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node-negative breast cancer who have estrogen-receptor-negative tumors. N Engl J Med, 320: 473–478, 1989.
2.
BonadonnaG., ValagussaP., MoliterniA.: Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N Engl J Med, 332: 901–906, 1995.
3.
Early Breast Cancer Trialists’ Collaborative Group:Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists’ Collaborative Group. Lancet, 352: 930–942, 1998.
4.
MartinM., PienkowskiT., MackeyJ.: TAC improves disease free survival and overall survival over FAC in node positive early breast cancer patients, BCIRG 001: 55 months follow-up. 26th Annual San Antonio Breast Cancer Symposium, Abstr 4, 2003. Available at www.sabcs.org.
5.
RochéH., FumoleauP., SpielmannM.: Five years analysis of the PACS 01 trial: 6 cycles of FEC100 vs 3 cycles of FEC100 followed by 3 cycles of docetaxel (D) for the adjuvant treatment of node positive breast cancer. Breast Cancer Res Treat, 88: S16(abstr 27), 2004.
6.
MartinM., LluchA., SeguiM.A.: Prophylactic growth factor (GF) support with adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node-negative breast cancer (BC): an interim safety analysis of the GE-ICAM 9805 study. Proc ASCO, 22: 32 (Abstr 620), 2004.
7.
VogelC.L., WojtukiewiczM.Z., CarrollR.R.: First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol, 23: 1178–1184, 2005
8.
RiveraE., HaimE.M., FridmanM.: First-cycle absolute neutrophil count can be used to improve chemotherapy-dose delivery and reduce the risk of febrile neutropenia in patients receiving adjuvant therapy: a validation study. Breast Cancer Res, 5: R114–R120, 2003.
9.
LymanG.H., DaleD.C., CrawfordJ.: Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. J Clin Oncol, 21: 4524–4531, 2003.
